DDInter778 DDInter1676
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Fosaprepitant {u} (Compound) resembles {v} (Compound) Aprepitant
Fosaprepitant {u} (Compound) binds {v} (Gene) TACR1
Fosaprepitant {u} (Compound) is included by {v} (Pharmacologic Class) Neurokinin 1 Antagonists
Fosaprepitant {u} (Compound) causes {v} (Side Effect) Type I hypersensitivity
Fosaprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Fosaprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Fosaprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Fosaprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Miconazole
Fosaprepitant {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Fosaprepitant {u} may lead to a major life threatening interaction when taken with {v} Terfenadine
Fosaprepitant (Compound) resembles Aprepitant (Compound)
Fosaprepitant (Compound) binds TACR1 (Gene)
Fosaprepitant (Compound) is included by Neurokinin 1 Antagonists (Pharmacologic Class)
Fosaprepitant (Compound) causes Type I hypersensitivity (Side Effect)
Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Miconazole
Fosaprepitant may lead to a major life threatening interaction when taken with Entrectinib
Fosaprepitant may lead to a major life threatening interaction when taken with Terfenadine